Aarti Drugs Q2 FY27 Earnings Shine As Profit Nearly Doubles To ₹82.8 Crore, Revenue Rises 27% To ₹828.8 Crore While 63% EBITDA Growth Signals Stronger Operating Performance
· Free Press Journal
Mumbai: Aarti Drugs reported strong financial results for the second quarter of FY27, with profit after tax (PAT) rising approximately 83 per cent year-on-year to ₹82.8 crore, compared with ₹45.2 crore in the corresponding quarter last year.
Revenue from operations increased 27 per cent to ₹828.8 crore during the July-September quarter, against ₹652.9 crore in Q2 FY26. The pharmaceutical company also reported improved operating profitability, supported by growth across its business segments.
Visit saltysenoritaaz.com for more information.
IOL Chemicals & Pharmaceuticals Q2 FY27 Net Profit More Than Doubles To ₹65 Crore, Revenue Up 40.1%Profit Growth
Aarti Drugs recorded earnings before interest, taxes, depreciation and amortisation (EBITDA) of ₹137.9 crore, marking a 63 per cent increase from ₹84.4 crore a year earlier. The EBITDA margin expanded by 370 basis points to 16.6 per cent, indicating improved operating profitability. The company's net profit increased by ₹37.6 crore compared with the year-ago period.
API Business
The active pharmaceutical ingredients (API) segment remained a major revenue contributor during the September quarter. Revenue from the API business increased 17 per cent year-on-year to ₹604.5 crore. The segment continued to account for a substantial portion of the company's overall quarterly revenue.
Formulation Growth
Aarti Drugs also recorded strong growth in its pharmaceutical formulations business. Revenue from formulations climbed 58 per cent to ₹130 crore during Q2 FY27. The increase highlighted the segment's expanding contribution to the company's financial performance.
Kwality Pharmaceuticals Reports 36% Revenue Growth, PAT Up 75% In Q4Chemical Revenue
The specialty chemicals business registered the highest percentage growth among the reported segments. Revenue from specialty chemicals surged 92 per cent to ₹71.8 crore, nearly doubling compared with the previous year.
Leadership Changes
The company also announced changes in its senior management following the retirement of Prakash Patil as Chairman, Managing Director and CEO on October 1, 2026. Rashesh Gogri assumed the position of Chairman, while Adhish Patil took charge as Managing Director.
Business Outlook
Aarti Drugs' September-quarter results reflected higher revenue, stronger operating earnings and improved margins. The performance of its API, formulations and specialty chemicals businesses will remain important factors to monitor in the coming quarters.
Disclaimer: This report is based on company exchange filings and is for informational purposes only. Investors should independently assess risks before investing.